Sixteen months experience with cyclosporin-A in human kidney transplantation.

CY-A is a potent immunosuppressive agent and can prevent graft rejection. In our experience hirsutism and viral infections are marked. Lymphomas may be more common in CY-A-treated patients than in those treated conventionally. Smaller doses of CY-A given for shorter periods before conversion to conventional treatment may be a better way to use this new agent.